Abstract
Patients with glomerulopathies are at an elevated risk for developing cancers due to a complex interplay of intrinsic immune dysfunction, age-related factors, comorbidities, and the effects of immunosuppressive therapies. Regular screening for malignancies is recommended, especially in high-risk groups such as those with membranous nephropathy or older patients, to facilitate early detection and improve outcomes.